CAMPSIITET Phase I/II/III: An interim clinical study update of RGX-121, an investigational gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II)

被引：0
|
作者：
Pisani, Laura [1 ]
Ficicioglu, Can [2 ]
Harmatz, Paul [3 ]
Giugliani, Roberto [4 ]
Rajan, Deepa [5 ]
Hagood, Joseph [1 ]
Fiscella, Michele [1 ]
Yang, Lin [1 ]
Gilmor, Michelle [1 ]
Cho, Yoonjin [1 ]
Mulatya, Caroline [1 ]
Phillips, Dawn [1 ]
Boulos, Nidal [1 ]
Falabella, Paulo [1 ]
机构：
[1] REGENXBIO Inc, Rockville, MD USA
[2] Childrens Hosp Philadelphia, Philadelphia, MD USA
[3] UCSF, Benioff Childrens Hosp Oakland, Oakland, CA USA
[4] Univ Fed Rio Grande do Sul, Dept Genet, Med Genet Serv, HCPA, Porto Alegre, RS, Brazil
[5] Univ Pittsburgh, Pittsburgh, PA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2024年 / 141卷 / 04期
关键词：
D O I：
10.1016/j.ymgme.2024.108245
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
069
引用
收藏
页数：1
相关论文
共 50 条
  • [21] RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in human study
    Wang, Raymond Y.
    Ficicioglu, Can H.
    Giugliani, Roberto
    Burke, Jenna
    Fiscella, Michele
    Yang, Lin
    Gilmor, Michelle
    Cho, Yoonjin
    Phillips, Dawn
    Falabella, Paulo
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 134 - 134
  • [22] RGX-111 Gene Therapy for the Treatment of Severe Mucopolysaccharidosis Type I (MPS I): Interim Analysis of Data from the First in Human Study
    Pisani, Laura
    Wang, Raymond
    Ficicioglu, Can
    Giugliani, Roberto
    Burke, Jenna
    Fiscella, Michele
    Yang, Lin
    Gilmor, Michelle
    Cho, Yoonjin
    Phillips, Dawn
    Falabella, Paulo
    MOLECULAR THERAPY, 2023, 31 (04) : 453 - 453
  • [23] Investigational intrathecal (IT) enzyme replacement therapy for the severe form of Hunter syndrome (mucopolysaccharidosis type II, MPS II)
    Muenzer, Joseph
    Hendriksz, Christian J.
    Stein, Margot B.
    Fan, Zheng
    Kearney, Shauna
    Horton, Johan
    Vijayaraghavan, Suresh
    Perry, Victor
    Santra, Saikat
    Solanki, Guirish A.
    Wang, Nan
    Mascelli, Mary Ann
    Pan, Luying
    Sciarapp, Kenneth
    Barbier, Ann J.
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S79 - S79
  • [24] RGX-111 GENE THERAPY FOR THE TREATMENT OF SEVERE MUCOPOLYSACCHARIDOSIS TYPE I (MPS I): INTERIM ANALYSIS OF DATA FROM THE FIRST IN HUMAN STUDY
    Gilmor, Michelle
    Wang, Raymond
    Ficicioglu, Can
    Giugliani, Roberto
    Burke, Jenna
    Fiscella, Michele
    Yang, Lin
    Phillips, Dawn
    Falabella, Paulo
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (03) : 50 - 50
  • [25] RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in-human study
    Wang, Raymond
    Ficiciolu, Can
    Giugliani, Roberto
    Nevoret, Marie-Laure
    Fiscella, Michele
    Yang, Lin
    Cho, Yoonjin
    Phillips, Dawn
    Falabella, Paulo
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S126 - S126
  • [26] Comparative dose effectiveness of intravenous and intrathecal AAV9.CB7.hIDS, RGX-121, in mucopolysaccharidosis type II mice
    Smith, Miles C.
    Belur, Lalitha R.
    Karlen, Andrea D.
    Erlanson, Olivia
    Furcich, Justin
    Lund, Troy C.
    Seelig, Davis
    Kitto, Kelley F.
    Fairbanks, Carolyn A.
    Kim, Kwi Hye
    Buss, Nick
    Mcivor, R. Scott
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32 (01)
  • [27] Long-Term Expression of HMI-203: Investigational Gene Therapy Candidate for Mucopolysaccharidosis Type II (MPS II), or Hunter Syndrome
    Smith, Laura
    Patel, Kruti
    Gingras, Jacinthe
    Tzianabos, Alec
    Schulman, Lindsay
    Zhivich, Victor
    Kivaa, Monicah
    Faulkner, Deiby
    Sengooba, Arnold
    Behmoiras, Liana
    Seabrook, Tania
    Dollive, Serena
    Avila, Nancy
    Zhao, Jingyan
    White, Yvonne
    Newman, Jenn
    Woodcock, Steve
    Smith, Sean
    Francone, Omar
    Seymour, Albert
    MOLECULAR THERAPY, 2021, 29 (04) : 247 - 247
  • [28] Clinical trial design for HMI-203 investigational gene therapy for mucopolysaccharidosis type II (MPS II) informed by cross-correction potential and KOL input
    Gingras, Jacinthe
    Haroldson, Jeff
    Smith, Laura J.
    Patel, Kruti
    Salstrom, Jen
    Jordan, Julie
    Cohn, Gabriel M.
    Francone, Omar
    Seymour, Albert
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S46 - S46
  • [29] Comparative effectiveness of intravenous and intrathecal AAV9. CB7.hIDS (RGX-121) in a murine model of mucopolysaccharidosis type II
    Smith, Miles C.
    Belur, Lalitha
    Erlanson, Olivia L.
    Furcich, Justin W.
    Karlen, Andrea D.
    Lund, Troy C.
    Buss, Nicholas
    McIvor, R. Scott
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S114 - S114
  • [30] A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)
    Muenzer, Joseph
    Wraith, James E.
    Beck, Michael
    Giugliani, Roberto
    Harmatz, Paul
    Eng, Christine M.
    Vellodi, Ashok
    Martin, Rick
    Ramaswami, Uma
    Gucsavas-Calikoglu, Muge
    Vijayaraghavan, Suresh
    Wendt, Suzanne
    Puga, Antonio
    Ulbrich, Brian
    Shinawi, Marwan
    Cleary, Maureen
    Piper, Diane
    Conway, Ann Marie
    Kimura, Alan
    GENETICS IN MEDICINE, 2006, 8 (08) : 465 - 473
12345